REVUFORJ (revumenib) tablets
REVUFORJ is a prescription medicine used to treat leukemia. FDA approved revumenib (brand name REVUFORJ) is not (yet) registered or available in India but on request Indian patient can buy REVUFORJ at the lowest price.
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
REVUFORJ (revumenib) tablets
Revumenib is used to treat acute leukemia with lysine methyltransferase 2A gene translocation (KMT2A) in patients
REVUFORJ is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.
Revumenib, sold under the brand name Revuforj, is an anti-cancer medication used for the treatment of acute leukemias harboring lysine methyltransferase 2A gene (KMT2A) rearrangements. It is designed to disrupt the interaction between menin and KMT2A (also known as MLL), which plays a role in the pathogenesis of these leukemias.
Revumenib was approved for medical use in the United States in November 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
REVUFORJ (revumenib) tablets, for oral use Initial U.S. Approval: 2024
—————-
Current Indication: Treat of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.
—————-
Marketed By: Syndax Pharmaceuticals, Inc.
—————-
Approval Date: : 2024
—————-
Active ingredient: revumenib
—————-
Tablets: 25 mg, 110 mg, 160 mg
Find Reference Updates
- For REVUFORJ (revumenib) tablets And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions.
- FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation
- Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
- About AML and ALL.
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
REVUFORJ (revumenib) tablets is generally considered a specialty medicine and may require specialized handling and distribution procedures. Where legally permitted, it may be sourced through international supply channels and transported under temperature-controlled conditions (2°C to 8°C) to maintain product integrity.
Patients and healthcare providers seeking information about access to this medicine may consult organizations that assist with administrative processes related to importation, documentation, customs procedures, and cold-chain logistics, subject to applicable laws, regulations, and product availability.
Alleviare Life Sciences Pvt. Ltd. act as facilitator for import of restricted and internationally sourced anti-cancer medicines into India. Alleviare Life Sciences is one such organization that may provide support services related to documentation, customs coordination, and temperature-controlled transportation. Patients should consult their treating physician and verify all regulatory requirements before pursuing access to any imported medicine.
Get in touch with support team of Alleviare Life Sciences Pvt. Ltd. to learn about available patient access and import facilitation options.
Contact the facilitator: Mr. Kamal
Address: Mezzanine Floor, S-9, Green Park Extension, South Delhi, Delhi, 110016
Call: @ +91-9289711087 / 9289711088
WhatsApp: @ +91-9289711087 / 9289711088
Email: info@alleviareindia.com
Website: www.alleviareindia.com
Get access to FDA approved medicines in India.
On request of patient, we have facilitated patient in import process to get delivered in time. If patients from following city in India looking for speciality medicines can contact us for the same – Ahmedabad, Bangalore, Surat, Kolkata, Pune, Indore, Nagpur, Agra, Kanpur, Patna, Coimbatore, Kochi, Delhi, Gurugram, Amaravati, Itanagar, Dispur, Patna, Raipur, Panaji, Gandhinagar, Chandigarh, Shimla, Ranchi, Bengaluru, Thiruvananthapuram, Bhopal, Mumbai, Imphal, Shillong, Aizawl, Kohima, Bhubaneswar, Jaipur, Gangtok, Chennai, Hyderabad, Agartala, Lucknow, Dehradun, Gairsain. Aizawal, Aurangabad, Barshi, Cachar, Dibrugarh, Karungapally, Kollam, Meghalaya, Mizoram, Sikkim, Pondichery, Punjab, Tripura, New Delhi, Agra, Gurugram, Alwar, Mathura, Panipat, Faridabad, Noida, Sonipat, Rohtak, Karnal, Ambala, Ghaziabad.